These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 23537460)
1. Impact of monthly prescription cap on medication persistence among patients with hypertension, hyperlipidemia, or diabetes. Wang CC; Wei D; Farley JF J Manag Care Pharm; 2013 Apr; 19(3):258-68. PubMed ID: 23537460 [TBL] [Abstract][Full Text] [Related]
2. Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study. Law MR; Lu CY; Soumerai SB; Graves AJ; LeCates RF; Zhang F; Ross-Degnan D; Adams AS Clin Ther; 2010 Apr; 32(4):729-41; discussion 716. PubMed ID: 20435243 [TBL] [Abstract][Full Text] [Related]
3. Factors associated with medication adherence and persistence of treatment for hypertension in a Medicaid population. Baggarly SA; Kemp RJ; Wang X; Magoun AD Res Social Adm Pharm; 2014; 10(6):e99-e112. PubMed ID: 24731547 [TBL] [Abstract][Full Text] [Related]
4. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population. Bergeson JG; Worley K; Louder A; Ward M; Graham J J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475 [TBL] [Abstract][Full Text] [Related]
5. Effect of Medicaid Policy Changes on Medication Adherence: Differences by Baseline Adherence. Amin K; Farley JF; Maciejewski ML; Domino ME J Manag Care Spec Pharm; 2017 Mar; 23(3):337-345. PubMed ID: 28230447 [TBL] [Abstract][Full Text] [Related]
6. Impact of Medicaid prescription copayments on use of antipsychotics and other medications in patients with schizophrenia. Doshi JA; Li P; Desai S; Marcus SC J Med Econ; 2017 Dec; 20(12):1252-1260. PubMed ID: 28792299 [TBL] [Abstract][Full Text] [Related]
7. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase. Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC J Manag Care Spec Pharm; 2014 Aug; 20(8):862-76. PubMed ID: 25062080 [TBL] [Abstract][Full Text] [Related]
8. Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications. Wilson J; Axelsen K; Tang S Am J Manag Care; 2005 Jan; 11 Spec No():SP27-34. PubMed ID: 15700907 [TBL] [Abstract][Full Text] [Related]
9. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics. Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766 [TBL] [Abstract][Full Text] [Related]
10. The impact of Medicare Part D on medication adherence among older adults enrolled in Medicare-Advantage products. Zhang Y; Lave JR; Donohue JM; Fischer MA; Chernew ME; Newhouse JP Med Care; 2010 May; 48(5):409-17. PubMed ID: 20393360 [TBL] [Abstract][Full Text] [Related]
11. Adherence to oral antidiabetic medications in the pediatric population with type 2 diabetes: a retrospective database analysis. Adeyemi AO; Rascati KL; Lawson KA; Strassels SA Clin Ther; 2012 Mar; 34(3):712-9. PubMed ID: 22381712 [TBL] [Abstract][Full Text] [Related]
12. Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan. Wake M; Oh A; Onishi Y; Guelfucci F; Shimasaki Y; Teramoto T Atherosclerosis; 2019 Mar; 282():19-28. PubMed ID: 30669019 [TBL] [Abstract][Full Text] [Related]
13. The impact of medication adherence on health outcomes for chronic metabolic diseases: a retrospective cohort study. Han E; Suh DC; Lee SM; Jang S Res Social Adm Pharm; 2014; 10(6):e87-e98. PubMed ID: 25088545 [TBL] [Abstract][Full Text] [Related]
14. Predictors of medication adherence and persistence in Medicaid enrollees with developmental disabilities and type 2 diabetes. Patel I; Erickson SR; Caldwell CH; Woolford SJ; Bagozzi RP; Chang J; Balkrishnan R Res Social Adm Pharm; 2016; 12(4):592-603. PubMed ID: 26522400 [TBL] [Abstract][Full Text] [Related]
15. Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study. Lu CY; Law MR; Soumerai SB; Graves AJ; LeCates RF; Zhang F; Ross-Degnan D; Adams AS Clin Ther; 2011 Jan; 33(1):135-44. PubMed ID: 21397779 [TBL] [Abstract][Full Text] [Related]
16. Effect of the Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia. Li P; McElligott S; Bergquist H; Schwartz JS; Doshi JA Ann Intern Med; 2012 Jun; 156(11):776-84, W-263, W-264, W-265, W-266, W-267, W-268, W-269. PubMed ID: 22665815 [TBL] [Abstract][Full Text] [Related]
17. Predicting Adherence to Chronic Disease Medications in Patients with Long-term Initial Medication Fills Using Indicators of Clinical Events and Health Behaviors. Lauffenburger JC; Franklin JM; Krumme AA; Shrank WH; Matlin OS; Spettell CM; Brill G; Choudhry NK J Manag Care Spec Pharm; 2018 May; 24(5):469-477. PubMed ID: 29694288 [TBL] [Abstract][Full Text] [Related]
18. Comparing adherence and persistence across 6 chronic medication classes. Yeaw J; Benner JS; Walt JG; Sian S; Smith DB J Manag Care Pharm; 2009; 15(9):728-40. PubMed ID: 19954264 [TBL] [Abstract][Full Text] [Related]
19. A retrospective database analysis of neuropathic pain and oral antidiabetic medication use and adherence among Texas adults with type 2 diabetes enrolled in Medicaid. Oladapo AO; Barner JC; Rascati KL; Strassels SA Clin Ther; 2012 Mar; 34(3):605-13. PubMed ID: 22386828 [TBL] [Abstract][Full Text] [Related]
20. A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs. loose-dose combination of oral anti-diabetes drugs. Lokhandwala T; Smith N; Sternhufvud C; Sörstadius E; Lee WC; Mukherjee J J Med Econ; 2016; 19(3):203-12. PubMed ID: 26473990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]